Trial · NCT07570316
Registered outcomes21
Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.
21 to 21 of 21
Download this page as JSON| List | Outcome | Time frame | Description |
|---|---|---|---|
| Secondary | Incidence of NAb against efgartigimod in serum and rHuPH20 in plasma | Up to 24 weeks (part A) + up to 135 weeks | NAb: neutralizing antibody(ies); rHuPH20: recombinant human hyaluronidase PH20. |
Source ClinicalTrials.govtrials-2026-11-12-0.4.0
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNone stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/trials/v1/NCT07570316/registered?page=2